Hepatitis B or hepatitis C coinfection in HIV-infected pregnant women in Europe

HIV Medicine

Volumn 9, Issue 7, 2008, Pages 526-534

  Landes, M ^a   Newell, M L ^b,c   Barlow, P ^d   Fiore, S ^e   Malyuta, R ^f   Martinelli, P ^g   Posokhova, S ^h   Savasi, V ^e   Semenenko, I ^f   Stelmah, A ⁱ   Tibaldi, C ^j   Thorne, Claire ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF MILAN   (Italy)

^f Perinatal Prevention of AIDS Initiative Odessa   (Ukraine)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h Odessa Regional Radio Broadcasting Center   (Ukraine)

ⁱ AIDS Centre of Crimea   (Ukraine)

^j CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

more..

Author keywords

Epidemiology; Hepatitis B; Hepatitis C; HIV; Pregnancy

Indexed keywords

EFAVIRENZ; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUROPE; FEMALE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MIXED INFECTION; NEGRO; NONHUMAN; PREGNANT WOMAN; PRIORITY JOURNAL; SEROPREVALENCE; SINGLE DRUG DOSE; THIRD TRIMESTER PREGNANCY; VIREMIA; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; EUROPE; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; PREGNANCY; PREVALENCE; RISK FACTORS; RNA, VIRAL; YOUNG ADULT;

EID: 50149117012     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00599.x     Document Type: Article

References (52)

1. Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 2006; 57: 815-818.
2. Alberti A, Clumeck N, Collins S et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-624.
3. Petrovic LM. HIV/HCV co-infection: Histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: A review article. Liver Int 2007; 27: 598-606.
4. Konopnicki D, Mocroft A, de Wit S et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601.
5. The D:A:D Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D Study. Arch Intern Med 2006; 166: 1632-1641.
6. Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073-1089.
7. Nunez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 2005; 5: 374-382.
8. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4: 241-249.
9. Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS 2006; 20: 1171-1179.
10. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288: 199-206.
11. Cooper CL, Breau C, Laroche A, Lee C, Garber G. Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co-infection. HIV Med 2006; 7: 32-37.
12. Santiago-Munoz P, Roberts S, Sheffield J, McElwee B, Wendel GD Jr. Prevalence of hepatitis B and C in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 2005; 193: 1270-1273.
13. Rouet F, Chaix ML, Inwoley A et al. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: The ANRS 1236 Study. J Med Virol 2004; 74: 34-40.
14. Simpore J, Savadogo A, Ilboudo D et al. Toxoplasma gondii, HCV, and HBV seroprevalence and co-infection among HIV-positive and - negative pregnant women in Burkina Faso. J Med Virol 2006; 78: 730-733.
15. Hershow RC, O'Driscoll PT, Handelsman E et al. Hepatitis C virus coinfection and HIV load, CD4 cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Clin Infect Dis 2005; 40: 859-867.
16. British HIV Association. Guidelines for the Management of HIV Infection in Pregnant Women and the Prevention of Mother-To-Child Transmission of HIV. London: British HIV Association, 2007, http://www.bhiva.org/ cms1221368.asp (accessed 15 January 2008).
17. England K, Thorne C, Newell ML. Vertically acquired paediatric coinfection with HIV and hepatitis C virus. Lancet Infect Dis 2006; 6: 83-90.
18. European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: Evolving in the East and established in the West. AIDS 2006; 20: 1419-1427.
19. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-974.
20. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study. Lancet 2000; 356: 1800-1805.
21. Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, Carballo E, Barrio E. Association of HCV and HBV markers in Spanish HIV-seropositive patients in relation to risk practices. Hepatogastroenterology 2003; 50: 2093-2097.
22. Rancinan C, Neau D, Saves M et al. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 2002; 16: 1357-1362.
23. Mohsen AH, Murad S, Easterbrook PJ. Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London. HIV Med 2005; 6: 206-215.
24. Menendez C, Sanchez-Tapias JM, Kahigwa E et al. Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania. J Med Virol 1999; 58: 215-220.
25. Apea-Kubi KA, Yamaguchi S, Sakyi B, Ofori-Adjei D. HTLV-1 and other viral sexually transmitted infections in antenatal and gynaecological patients in Ghana. West Afr J Med 2006; 25: 17-21.
26. Thio CL, Seaberg EC, Skolasky R Jr. et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926.
27. Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992-1002.
28. Mocroft A, Phillips AN, Soriano V et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005; 21: 527-536.
29. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 23-31.
30. Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268.
31. Perinatal HIV Guidelines Working Group. Safety and toxicity of individual antiretroviral agents in pregnancy (2 November 2007). Supplement to PHSTF Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States, 2007. http://aidsinfo.nih.gov (accessed 15 January 2008).
32. Hitti J, Frenkel LM, Stek AM et al. Maternal toxicity with continuous nevirapine in pregnancy. J Acquir Immune Defic Syndr 2004; 36: 772-776.
33. Lyons F, Hopkins S, Kelleher B et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006; 7: 255-260.
34. Natarajan U, Pym A, McDonald C et al. Safety of nevirapine in pregnancy. HIV Med 2007; 8: 64-69.
35. Jamisse L, Balkus J, Hitti J et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007; 44: 371-376.
36. Joao EC, Calvet GA, Menezes JA et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol 2006; 194: 199-202.
37. Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States, 2 November 2007. http://AIDSinfo.nih.gov (accessed 15 January 2008).
38. Rendina D, Vigorita E, Bonavolta R et al. HCV and GBV-c/HGV infection in HIV positive patients in southern Italy. Eur J Epidemiol 2001; 17: 801-807.
39. Department of Health and Human Sciences Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 1 December 2007. United States Department of Health and Human Sciences; 2007. http://AIDSinfo.nih.gov (accessed 15 January 2008).
40. Soriano V, Puoti M, Bonacini M et al. Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV International Panel. AIDS 2005; 19: 221-40.
41. Nunez M, Soriano V. Hepatitis C virus (HCV) genotypes and disease progression in HIV/HCV-coinfected patients. J Infect Dis 2005; 191: 1-3.
42. Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997; 175: 164-168.
43. Yoo TW, Donfield S, Lail A, Lynn HS, Daar ES. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis 2005; 191: 4-10.
44. European Paediatric HCV Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005; 41: 45-51.
45. Ramos B, Nunez M, Toro C et al. Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients. J Infect 2007; 54: 173-179.
46. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. J Viral Hepat 2006; 13: 34-41.
47. Di Bisceglie AM. Natural history of hepatitis C: Its impact on clinical management. Hepatology 2000; 31: 1014-1018.
48. Grebely J, Raffa JD, Lai C et al. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol 2007; 21: 447-451.
49. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA 2000; 284: 450-456.
50. Piasecki BA, Lewis JD, Reddy KR et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology 2004; 40: 892-899.
51. Piroth L, Sene D, Pol S et al. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS 2007; 21: 1323-1331.
52. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: Systematic review and meta-analysis. BMJ 2006; 332: 328-336.